New England Journal of MedicineOriginal article
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma
Data ReadoutTalquetamab–DaratumumabNeutral
AI Analysis
Summary
A New England Journal of Medicine publication presents data on Talquetamab–Daratumumab combination therapy for relapsed or refractory myeloma. The article represents a peer-reviewed data readout in a major medical journal.
Clinical Trial Data
Importance:5/10
Sentiment:
0.00
myelomacombination_therapypublished_data
Related Companies
Read the original article
Published by New England Journal of Medicine on June 13, 2026 10:00 AM